Page 6 - Frazier Life Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PepGen Stock Higher After Follow-on Offering

By Rob Curran Shares of PepGen rallied after the biotech company priced a follow-on offering of 7.5 million shares around Tuesday's closing price. The.

Rob curranFrazier life sciencesAdage capital partnersJanus henderson investorsLaurion capital managementMonashee investment managementOctagon capitalPerceptive advisorsArticle normalBiotechnology servicesTrusts funds financial vehiclesPrivate equityFinancial investment servicesInvestment advice research servicesScientific research servicesHealthcare life sciences

PepGen Announces Pricing of $80 1 Million Underwritten Offering of Common Stock

BOSTON, Feb. 07, 2024 PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe.

United statesSarah suttonLaurence wattsPepgen incExchange commissionSyndicate departmentLeerink partnersFrazier life sciencesGilmartin groupJanus henderson investorsLaurion capital managementMonashee investment managementOctagon capitalPerceptive advisorsEnhanced delivery oligonucleotide

New ophthalmology company hits the market

"Ascendis Pharma partners with Frazier Life Sciences, RA Capital Management, venBio, and HealthQuest Capital to launch ophthalmology company Eyconis. Eyconis wi

Emmett cunninghamOliver boris stauchAscendis pharmaAscendi transconFrazier life sciencesHealthquest capitalRedwood cityMeta name keywords content ascendis pharmaInvestor syndicateFrazier life sciencesMa capital managementHealthquest capitalPhthalmology companyExclusive rights

New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million

COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created

United statesRedwood cityConrad wangDanna chenEmmett cunninghamDaniel estesAscendis pharmaYvonne yamanakaJan mikkelsenOliver boris stauchFrazier life sciences of eyconis incExchange commissionFrazier life sciencesSenior partnerHealthquest capitalExecutive chairman

Ascendis, Frazier launch new ophthalmology company called Eyconis (NASDAQ:ASND)

Ascendis, Frazier launch new ophthalmology company called Eyconis (NASDAQ:ASND)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Emmett cunninghamMaksim labkouskiAscendis transconFrazier life sciencesRedwood cityHealthquest senior partner